Etoposid Ebewe

Etoposid Ebewe



EBEWE Pharma




Mega Lifesciences
Concise Prescribing Info
Recurrent or refractory testicular cancer, small-cell lung cancer, Hodgkin's & non-Hodgkin's lymphoma, acute myeloid leukaemia, gestational trophoblastic neoplasia, ovarian cancer.
Dosage/Direction for Use
Adult 50-100 mg/m2 daily by slow IV infusion over 30-60 min on days 1-5 or 100-120 mg/m2 by slow IV infusion over 30-60 min on days 1, 3 & 5 every 3-4 wk in combination w/ other drugs indicated in the disease to be treated. Paed Hodgkin's & non-Hodgkin's lymphoma, acute myeloid leukaemia 75-150 mg/m2 daily by slow IV infusion over 30-60 min for 2-5 days in combination w/ other antineoplastic agents. Renal impairment >50 mL/min 100% of dose, 15-50 mL/min 75% of dose.
Hypersensitivity. Concomitant use of yellow fever or live vaccines in immunosuppressed patients. Lactation.
Special Precautions
Reduce dose or discontinue treatment if severe reactions occur. Myelosuppression; secondary leukaemia; low serum albumin may be at increased risk of etoposide toxicities; tumour lysis syndrome. Measure haematological parameters (eg, platelet count, haemoglobin, WBC count & differential) at start of therapy & prior to each subsequent dose. May cause adverse reactions that affect ability to drive or use machines. Reduce dose in renal impairment. Monitor hepatic function regularly. Men & women should use effective contraception during treatment & up to 6 mth after treatment. Pregnancy. Paed <18 yr.
Adverse Reactions
Anaemia, leucopenia, myelosuppression, neutropenia, thrombocytopenia; abdominal pain, anorexia, constipation, nausea & vomiting; hepatotoxicity, increased ALT, alkaline phosphatase, AST, bilirubin; alopecia, pigmentation; asthenia, malaise. Infection; acute leukaemia; anaphylactic reactions; dizziness; arrhythmia, MI; HTN, transient systolic hypotension following rapid IV administration; diarrhoea, mucositis (including stomatitis & oesophagitis); pruritus, rash, urticaria; extravasation, phlebitis.
Drug Interactions
Increased exposure & decreased total body clearance w/ high dose ciclosporin. Reduced total body clearance w/ cisplatin. Increased clearance & reduced efficacy w/ phenytoin & other enzyme-inducing antiepileptic. Efficacy may be reduced w/ drugs known to inhibit phosphatase activity. May be displaced from plasma protein binding by phenylbutazone, Na salicylate & aspirin. Decreased seizure control w/ antiepileptic drugs. May elevate INR w/ warfarin. Increased risk of fatal systemic vaccinal disease w/ yellow fever vaccine, live vaccines (contraindicated). May have additive or synergetic effects w/ other drugs w/ similar myelosuppressant action. Cross resistance w/ anthracyclines.
MIMS Class
Cytotoxic Chemotherapy
ATC Classification
L01CB01 - etoposide ; Belongs to the class of plant alkaloids and other natural products, podophyllotoxin derivatives. Used in the treatment of cancer.
Etoposid Ebewe soln for infusion 20 mg/mL
5 mL x 1's
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in